about
Potential role of G protein-coupled receptor (GPCR) heterodimerization in neuropsychiatric disorders: a focus on depressionEffect of repeated treatment with tianeptine and fluoxetine on central dopamine D(2) /D(3) receptorsActive versus passive cocaine administration: differences in the neuroadaptive changes in the brain dopaminergic systemIn vitro fluorescence studies of transcription factor IIB-DNA interaction.Role of silent polymorphisms within the dopamine D1 receptor associated with schizophrenia on D1-D2 receptor hetero-dimerization.Effects of joint administration of imipramine and amantadine in patients with drug-resistant unipolar depression.Effect of clozapine on ketamine-induced deficits in attentional set shift task in miceFluorescence studies reveal heterodimerization of dopamine D1 and D2 receptors in the plasma membrane.Genetic variants of dopamine D2 receptor impact heterodimerization with dopamine D1 receptor.Antidepressant drugs promote the heterodimerization of the dopamine D2 and somatostatin Sst5 receptors--fluorescence in vitro studies.Mechanism of action of clozapine in the context of dopamine D1-D2 receptor hetero-dimerization--a working hypothesis.Brain dopamine receptors--research perspectives and potential sites of regulation.Intrahepatic expression of genes related to metabotropic receptors in chronic hepatitis.Analysis of region-specific changes in gene expression upon treatment with citalopram and desipramine reveals temporal dynamics in response to antidepressant drugs at the transcriptome levelChronic mild stress alters the somatostatin receptors in the rat brain.Mesolimbic dopamine D₂ receptor plasticity contributes to stress resilience in rats subjected to chronic mild stresscAMP receptor protein from escherichia coli as a model of signal transduction in proteins--a review.Involvement of prolactin and somatostatin in depression and the mechanism of action of antidepressant drugs.The role of dopamine D2 receptor in the behavioral effects of imipramine--study with the use of antisense oligonucleotides.An investigation of the affinities, specificity and kinetics involved in the interaction between the Yin Yang 1 transcription factor and DNA.Norepinephrine transporter (NET) knock-out upregulates dopamine and serotonin transporters in the mouse brain.Repeated administration of antidepressant drugs affects the levels of mRNA coding for D1 and D2 dopamine receptors in the rat brain.Optimized procedure of extraction, purification and proteomic analysis of nuclear proteins from mouse brain.Proteomic and bioinformatic analysis of a nuclear intrinsically disordered proteome.Dopamine D2 and serotonin 5-HT1A receptor interaction in the context of the effects of antipsychotics - in vitro studies.Encapsulation of clozapine in polymeric nanocapsules and its biological effects.Biocompatible Polymeric Nanoparticles as Promising Candidates for Drug Delivery.Basal prolactin levels in rat plasma correlates with response to antidepressant treatment in animal model of depression.Prolactin and its receptors in the chronic mild stress rat model of depression.Differential stress response in rats subjected to chronic mild stress is accompanied by changes in CRH-family gene expression at the pituitary level.Time-dependent miR-16 serum fluctuations together with reciprocal changes in the expression level of miR-16 in mesocortical circuit contribute to stress resilient phenotype in chronic mild stress - An animal model of depression.Reciprocal MicroRNA Expression in Mesocortical Circuit and Its Interplay with Serotonin Transporter Define Resilient Rats in the Chronic Mild Stress.Hetero-dimerization of serotonin 5-HT(2A) and dopamine D(2) receptors.Studies on the role of the receptor protein motifs possibly involved in electrostatic interactions on the dopamine D1 and D2 receptor oligomerization.The role of D1-D2 receptor hetero-dimerization in the mechanism of action of clozapine.Flow cytometry application for studies on adenosine A2A receptors expression.Fluorescence studies of homooligomerization of adenosine A2A and serotonin 5-HT1A receptors reveal the specificity of receptor interactions in the plasma membrane.Neuronal cell lines transfected with the dopamine D2 receptor gene promoter as a model for studying the effects of antidepressant drugs.New insights into the model of dopamine D1 receptor and G-proteins interactions.Pharmacological profile of venlafaxine, a new antidepressant, given acutely.
P50
Q26823350-76537D0D-E0A9-4AA6-B54F-82E9DAE91EC1Q28216067-833C6FB7-0C51-47CB-9085-8EDDB5A7DF9CQ28304806-1E490B4B-EF5C-4151-94CD-9E67DC33F78DQ30378061-6E682523-44A3-48E8-858C-23A53C043B75Q30384528-2F220CC6-AB3F-4F2E-A501-D66F75FBA93BQ33211068-632EB5D7-1779-4926-92F5-0D6AB879FD3FQ33841881-93E19BE0-64FA-40AC-B248-6CC33FE7248BQ34548244-2C11AB77-BD31-4E11-8EEF-0A6F1144F90BQ34549957-0EA9FB45-44AF-418D-A9DF-1AE97CD915F1Q34660962-DEA09305-EBE7-45F7-AB41-A3DAC3318D24Q34898825-51F10CEC-BB5B-4A53-872D-EE4C87293C13Q36015727-233F6D63-72FC-41F6-A1B5-187493AD92FBQ36175058-CFB12E16-429C-49F3-BEC9-FA4B29FF6115Q36223676-53B821C1-C455-43B2-86E0-7D102398DBACQ36427074-5CCBCBC9-1395-4953-8636-370994539DEEQ36872755-D2218255-5BEC-446B-86AF-07F0A69AAE3EQ37334758-0723FA76-5D40-4DF9-94DA-1CF7DE05D8A0Q38189564-F859F16D-3488-4E71-90E8-3106A6994B8CQ38307918-CB4F6DB7-56A3-461E-8F82-8C1D2F0B1450Q38323727-B7F2875B-CD7B-4217-8AA6-A899D1A43B5AQ38334086-C2912023-4745-4832-9317-4B71E7C81866Q38349774-0429D5CA-F864-49EE-93D3-940F9CC9AEFEQ38453125-289EBE1B-DE4A-47BE-9F21-F6311F1AC3BCQ38457765-75C4EA86-0A09-4EF8-8542-583BD25B4F5BQ38794247-88575BDD-285F-4477-A1EA-146D323B834EQ38802905-5871380A-D59F-47DC-BE36-12D4AACFF950Q38870679-8B30EAF2-ED48-4290-BDCF-49A891FA71E2Q38881298-E5487677-DE78-400F-9958-8B2D34B901ECQ39261959-0E7FD78C-2C89-469F-A12B-96E38A1EAE58Q39268827-93FF4CD3-2777-4C9B-B707-60B907F6ED3FQ39284543-5EB128BB-6780-438D-BAC0-7F3613EE7046Q39297585-C4280317-E4BD-4631-BEA7-CCD9873F626AQ39657147-B1D0FFE6-4373-470E-868D-5352F20DCEA5Q39895376-A35C32A4-5954-47FD-85BB-DFB6E99A1E34Q39972845-DD24C983-95EA-4844-ADF8-F02FC3548B0FQ39974530-551B6BE9-90E2-4A42-BA5A-8C0AC23BEBF0Q40074976-2C43C7FB-3DDD-4AC7-ACF9-385887792FA1Q40521009-35F80F20-1DCA-4310-B1B3-F31E1ACA01C9Q41665877-6E04B698-CC47-4A0A-B46B-A9EA2486269CQ42538620-885CAA79-DCEE-4F79-84DD-21BC3E800DA8
P50
description
Forscher
@de
Polish pharmacologist
@en
Pools farmacologe
@nl
chercheur
@fr
hulumtuese
@sq
investigador
@es
polska farmakolog
@pl
ricercatore
@it
研究者
@zh
name
Marta Dziedzicka-Wasylewska
@ast
Marta Dziedzicka-Wasylewska
@ca
Marta Dziedzicka-Wasylewska
@cs
Marta Dziedzicka-Wasylewska
@en
Marta Dziedzicka-Wasylewska
@es
Marta Dziedzicka-Wasylewska
@gl
Marta Dziedzicka-Wasylewska
@hr
Marta Dziedzicka-Wasylewska
@hsb
Marta Dziedzicka-Wasylewska
@it
Marta Dziedzicka-Wasylewska
@nl
type
label
Marta Dziedzicka-Wasylewska
@ast
Marta Dziedzicka-Wasylewska
@ca
Marta Dziedzicka-Wasylewska
@cs
Marta Dziedzicka-Wasylewska
@en
Marta Dziedzicka-Wasylewska
@es
Marta Dziedzicka-Wasylewska
@gl
Marta Dziedzicka-Wasylewska
@hr
Marta Dziedzicka-Wasylewska
@hsb
Marta Dziedzicka-Wasylewska
@it
Marta Dziedzicka-Wasylewska
@nl
prefLabel
Marta Dziedzicka-Wasylewska
@ast
Marta Dziedzicka-Wasylewska
@ca
Marta Dziedzicka-Wasylewska
@cs
Marta Dziedzicka-Wasylewska
@en
Marta Dziedzicka-Wasylewska
@es
Marta Dziedzicka-Wasylewska
@gl
Marta Dziedzicka-Wasylewska
@hr
Marta Dziedzicka-Wasylewska
@hsb
Marta Dziedzicka-Wasylewska
@it
Marta Dziedzicka-Wasylewska
@nl
P214
P106
P1153
7004096219
P1412
P1559
Marta Dziedzicka-Wasylewska
@pl
P21
P214
P27
P31
P3124
P496
0000-0001-7030-7874
P735
P7859
viaf-165576152